Levetiracetam monotherapy in children with epilepsy: Experience from a tertiary pediatric neurology center.

Abstract

OBJECTIVES:

Levetiracetam (LEV) is a second-generation antiepileptic drug with high efficacy and tolerability in children and adults with epilepsy. We aimed to retrospectively assess the long-term efficacy, tolerability, and safety of LEV monotherapy in children with epilepsy.

METHODS:

All patients who received LEV monotherapy at the Ankara University Children Hospital between January 2010 and June 2020 were evaluated. This retrospective pediatric cohort study determined the efficacy and safety of LEV monotherapy in 281 outpatients with epilepsy.

RESULTS:

There were 281 patients, 50.5% female, aged 5 months to 18 years with a mean age of 9 years. Of these, 48% of patients had idiopathic epilepsy, 40.6% had symptomatic epilepsy, and 11,4% had cryptogenic/genetic epilepsy. Primary generalized seizures occurred in 61.6% of patients, focal seizures in 19.6%, both generalized and focal seizures in 15,3%, focal to bilateral tonic-clonic seizures in 2.5%, and undefined type of seizure in 1.1%. A total of 22.8% patients had an accompanying extra neurological disease, mostly cardiological and hematological. The range of final daily dose was 10-71 mg/kg/day, with mean 29.5 mg/kg/day. Duration of therapy ranged from 7 days to 96 months, with median 12 months (IQR: 6-22). For the all cohort, a 6th month retention rate was 81%, a 12th month retention rate was 71.4%, and a 24th month retention rate was 61.8%. Eighty five percent of the patients had a seizure reduction of at least 50% and 55.9% of patients remained seizure-free for median 12 months treatment duration with LEV monotherapy. Improvement of electroencephalography (EEG) findings was found in 42% of patients on control EEGs. A total of 67 adverse events were documented in 45 (16%) patients. The most common adverse events were behavioral problems such as aggression (n:18) and irritability (n:17). The discontinuation rate due to adverse events was 2.5%, and due to inefficacy was 5.3%.

CONCLUSION:

The present study suggests that the high retention rates, high percentage of seizure reduction, the low discontinuation rate due to adverse events and inefficacy, and the relatively benign and transient profile of adverse events make LEV preferable as monotherapy in the pediatric population.

• Authors: Miraç Yıldırım, Ömer Bektaş, Özben Akıncı Göktaş, Merve Feyza Yüksel, Süleyman Şahin, Serap Tıraş Teber
• Journal: Epilepsy & behavior : E&B (Epilepsy Behav) Vol. 116 Pg. 107745 (03 2021) ISSN: 1525-5069 [Electronic] United States
• PMID: 33508749 (Publication Type: Journal Article)
• Copyright: Copyright © 2020 Elsevier Inc. All rights reserved.

Chemical References

• Anticonvulsants
• Levetiracetam
• Piracetam

Topics

• Adult
• Anticonvulsants (adverse effects)
• Child
• Cohort Studies
• Epilepsy (drug therapy)
• Female
• Humans
• Levetiracetam (therapeutic use)
• Male
• Neurology
• Piracetam (therapeutic use)
• Retrospective Studies
• Treatment Outcome